title: Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.
abstract: The objective of the study was to evaluate the effect of parathyroidectomy (PTX) versus 35 mg once-weekly (ow) risedronate administration on volumetric bone mineral density (vBMD) and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism (PHPT). Our open-label prospective observational study included 32 postmenopausal women with PHPT as the study group: 16 underwent PTX and 16 were treated with 35 mg ow risedronate for 2 years. We assessed areal BMD (aBMD) by DXA, and vBMD and bone mineral content (BMC) (cortical and trabecular area) by peripheral quantitative computed tomography (pQCT) at the tibia at baseline and at 2 years. Risedronate did not result in any significant change on vBMD and structural pQCT indices. PTX resulted in significant increase in trabecular (trab) BMC (6.44 %) and vBMD (4.64 %), with percent increase being significantly higher than risedronate (p < 0.05). At cortical sites, there was no significant change following PTX. However, the percent change in cortical (cort) vBMD was higher following PTX versus risedronate (0.39 % vs. -0.26 %, p < 0.05). In conclusion, in postmenopausal women with PHPT, PTX is superior to ow risedronate, in terms of improvement of trabecular mineralization and vBMD at the tibia, whereas the effect at cortical sites is less pronounced.
authors.affiliation: Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", University of Athens, KAT Hospital, 10 Athinas Str. Kifissia, 14561, Athens, Greece, stournis@med.uoa.gr.
authors.forename: Symeon
authors.initials: S
authors.lastname: Tournis
authors.forename: Eleni
authors.initials: E
authors.lastname: Fakidari
authors.forename: Ismene
authors.initials: I
authors.lastname: Dontas
authors.forename: Chrysoula
authors.initials: C
authors.lastname: Liakou
authors.forename: Julia
authors.initials: J
authors.lastname: Antoniou
authors.forename: Antonis
authors.initials: A
authors.lastname: Galanos
authors.forename: Helen
authors.initials: H
authors.lastname: Marketou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Makris
authors.forename: Katerina
authors.initials: K
authors.lastname: Katsalira
authors.forename: George
authors.initials: G
authors.lastname: Trovas
authors.forename: George P
authors.initials: GP
authors.lastname: Lyritis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papaioannou
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D016105:Parathyroidectomy; D017698:Postmenopause; D000068296:Risedronic Acid; D013977:Tibia / Q000187:drug effects* / Q000473:pathology; D044465:White People
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid